CoChat

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

Open access
Findling, Robert L., Candler, Shawn A., Nasser, Azmi F., Schwabe, Stefan, Yu, Chungping, Garcia-Olivares, Jennie, O’Neal, Welton, Newcorn, Jeffrey H. · 2021 · CNS Drugs

The DOI matches its Crossref record; 88 of the 91 references it cites were found in a registry or an index.

Abstract

Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotoninergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-021-00825-w

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The chemical structure of viloxazine
Fig. 1 The chemical structure of viloxazineCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Research works printed but not linked: 6

  1. Marsh W. Viloxazine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Amsterdam: Elsevier Inc; 2007.
  2. National Center for Biotechnology Information, PubChem database. Viloxazine, CID = 5666. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed 17 Jan 2019.
  3. Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:122–5.
  4. Greenwood DT. Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3:18–28.
  5. Turner P, Bayliss PFC, Ghose K. Clinical pharmacoolgy of viloxazine (Vivalan). J Int Med Res. 1975;3:41–7.
  6. Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:112–5.

Cited by

See all 55

Metadata

Authors
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H.
Affiliations
  • Virginia Commonwealth University (US)
  • Supernus Pharmaceuticals (United States) (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Findling, Robert L.
Venue
CNS Drugs
Published
2021-05-18
Volume
35
Issue
6
Pages
643-653
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3160925470
Cited by
55
References
91
Citations by year
2026: 6 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 16 · 2021: 2
FWCI
1.83
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Sunovion
  • Supernus Pharmaceuticals
  • National Institute of Child Health and Human Development
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
viloxazine, antidepressants, attention deficit hyperactivity disorder, drug repurposing, sustained-release formulation, norepinephrine reuptake inhibitors, serotonergic system, cardiotoxicity, gastrointestinal adverse effects, drug safety and tolerability, mechanism of action
MeSH terms
Administration, Oral, Animals, Attention Deficit Disorder with Hyperactivity, Central Nervous System Diseases, Delayed-Action Preparations, Humans, Viloxazine, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. https://app.cochat.ai/papers/10.1007/s40263-021-00825-w
The paper
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021). Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. https://doi.org/10.1007/s40263-021-00825-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.